Structured evidence table for Vitamin E Visual Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin E Visual Performance Randomized Trial | Whilst intraocular pressure (IOP) reduction remains the only evidence-based treatment strategy, disease progression commonly occurs despite adequate IOP control, indicating that IOP-independent mechanisms play critical roles in RGC degeneration. | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Vitamin E Visual Performance Randomized Trial | This review synthesizes the current landscape of drug-based neuroprotective strategies, delineates preclinical from clinical evidence, and highlights emerging therapeutic targets. | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Vitamin E Visual Performance Randomized Trial | Clinical evidence is detailed inand a summary including preclinical and clinical evidence is shown in. | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Vitamin E Visual Performance Randomized Trial | These include excitotoxicity, mitochondrial dysfunction, oxidative stress, neuroinflammation, neurotrophic factor deprivation, and apoptosis (independently or in concert). | 4 | Rho Seungsoo (2026) | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies |
| Vitamin E Visual Performance Randomized Trial | In MS patients, higher vitamin E levels were associated with better cognitive performance and lower disability. | 4 | Bruno F (2026) | Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms. |
| Vitamin E Visual Performance Randomized Trial | No significant relationship was found between vitamin E levels and depressive symptoms. | 4 | Bruno F (2026) | Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms. |
| Vitamin E Visual Performance Randomized Trial | Longitudinal studies are needed to clarify whether low vitamin E levels influence the risk of developing MS, while randomized controlled trials are warranted to determine whether vitamin E supplementation may provide clinical benefits. | 4 | Bruno F (2026) | Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms. |
| Vitamin E Visual Performance Randomized Trial | Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system and the most common neurodegenerative disease in young adults, characterized by motor, sensory, visual, and cognitive impairments. | 4 | Bruno F (2026) | Serum Vitamin E Levels in Multiple Sclerosis: Association with Diagnosis, Cognitive Function, Disability, and Depressive Symptoms. |
Source documents